Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Phosphatidylinositol 3-Kinases"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 31610
Tytuł:
Structural Basis for Highly Selective Class II Alpha Phosphoinositide-3-Kinase Inhibition.
Autorzy:
Kücükdisli M; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, 13125 Berlin, Germany.
Bel-Abed H; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, 13125 Berlin, Germany.
Cirillo D; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, 13125 Berlin, Germany.
Lo WT; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, 13125 Berlin, Germany.
Efrém NL; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, 13125 Berlin, Germany.
Horatscheck A; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, 13125 Berlin, Germany.
Perepelittchenko L; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, 13125 Berlin, Germany.
Prokofeva P; Chair of Proteomics and Bioanalytics, Technical University of Munich, 85354 Freising, Germany.
Ehret TAL; Institute of Pharmaceutical Chemistry, Johann Wolfgang Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany.; Buchmann Institute for Molecular Life Sciences and Structural Genomics Consortium (SGC), Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany.
Radetzki S; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, 13125 Berlin, Germany.
Neuenschwander M; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, 13125 Berlin, Germany.
Specker E; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, 13125 Berlin, Germany.
Médard G; Chair of Proteomics and Bioanalytics, Technical University of Munich, 85354 Freising, Germany.
Müller S; Institute of Pharmaceutical Chemistry, Johann Wolfgang Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany.; Buchmann Institute for Molecular Life Sciences and Structural Genomics Consortium (SGC), Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany.
Wilhelm S; Chair of Proteomics and Bioanalytics, Technical University of Munich, 85354 Freising, Germany.
Kuster B; Chair of Proteomics and Bioanalytics, Technical University of Munich, 85354 Freising, Germany.
von Kries JP; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, 13125 Berlin, Germany.
Haucke V; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, 13125 Berlin, Germany.
Nazaré M; Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, 13125 Berlin, Germany.
Pokaż więcej
Źródło:
Journal of medicinal chemistry [J Med Chem] 2023 Oct 26; Vol. 66 (20), pp. 14278-14302. Date of Electronic Publication: 2023 Oct 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Phosphatidylinositol 3-Kinase*
Class II Phosphatidylinositol 3-Kinases*
Phosphatidylinositol 3-Kinases/metabolism ; Signal Transduction ; Protein Isoforms ; Phosphatidylinositols
Czasopismo naukowe
Szczegóły
Tytuł:
Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer.
Autorzy:
Park YS; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim J; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Ryu YS; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
Moon JH; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
Shin YJ; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
Kim JH; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
Hong SW; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
Jung SA; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
Lee S; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
Kim SM; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
Lee DH; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
Kim DY; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Yun H; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
You JE; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Yoon DI; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim CH; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Koh DI; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
Jin DH; Department of Pharmacology, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Department of Convergence Medicine, Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2023 Dec 31; Vol. 24 (1), pp. 2246208.
Typ publikacji:
Journal Article
MeSH Terms:
Phosphatidylinositol 3-Kinases*/genetics
Colonic Neoplasms*/drug therapy
Colonic Neoplasms*/genetics
Humans ; Cetuximab/pharmacology ; Cetuximab/therapeutic use ; Biomarkers ; Class I Phosphatidylinositol 3-Kinases/genetics ; Proto-Oncogene Proteins c-pim-1/genetics
Czasopismo naukowe
Szczegóły
Tytuł:
A Rare Pathological Phenotype of Endometrioid Serous and Clear-Cell Ovarian Cancer with PIK3CA Mutations in Relation to The Excellent Response of Alpelisib.
Autorzy:
Bayram E; Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana 01250, Turkey.
Khatib G; Department of Obstetrics and Gynecology, Cukurova University Faculty of Medicine, Adana 01250, Turkey.
Guney B; Department of Nuclear Medicine, Cukurova University Faculty of Medicine, Adana 01250, Turkey.
Kilicbagir E; Department of Pathology, Cukurova University Faculty of Medicine, Adana 01250, Turkey.
Gulec HR; Department of Biotechnology, Cukurova University Institute of Natural and Applied Sciences, Adana 01250, Turkey.
Boga I; AGENTEM (Adana Genetic Diseases Diagnosis and Treatment Center) and Medical Genetics Department of Medical Faculty, Cukurova University, Adana 01250, Turkey.
Paydas S; Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana 01250, Turkey.
Pokaż więcej
Źródło:
Genes [Genes (Basel)] 2023 Aug 16; Vol. 14 (8). Date of Electronic Publication: 2023 Aug 16.
Typ publikacji:
Case Reports
MeSH Terms:
Phosphatidylinositol 3-Kinases*/genetics
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Female ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/genetics ; Class I Phosphatidylinositol 3-Kinases/genetics
Raport
Szczegóły
Tytuł:
Leniolisib: First Approval.
Autorzy:
Duggan S; Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. .
Al-Salama ZT; Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Pokaż więcej
Źródło:
Drugs [Drugs] 2023 Jul; Vol. 83 (10), pp. 943-948.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Phosphatidylinositol 3-Kinases*
Immunologic Deficiency Syndromes*
Adult ; Humans ; Child ; Class I Phosphatidylinositol 3-Kinases ; Pyridines/pharmacology
Czasopismo naukowe
Szczegóły
Tytuł:
Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity.
Autorzy:
Sterba M; Department of Paediatrics, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic.; Department of Paediatric Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Cernopolni 212/9, 613 00, Brno, Czech Republic.
Pokorna P; Department of Biology, Faculty of Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Faberova R; Department of Paediatrics, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic.
Pinkova B; Department of Paediatrics, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic.
Skotakova J; Department of Paediatric Radiology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic.
Seehofnerova A; Department of Paediatric Radiology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic.
Blatny J; Department of Paediatrics, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic.
Janigova L; Department of Paediatric Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Cernopolni 212/9, 613 00, Brno, Czech Republic.
Koskova O; Department of Paediatric Surgery, Orthopaedics and Traumatology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic.
Palova H; Department of Biology, Faculty of Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Mahdal M; 1st Department of Orthopaedics, Faculty of Medicine, St. Anne's University Hospital Brno, Masaryk University, Brno, Czech Republic.
Pazourek L; 1st Department of Orthopaedics, Faculty of Medicine, St. Anne's University Hospital Brno, Masaryk University, Brno, Czech Republic.
Jabandziev P; Department of Paediatrics, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic.; Department of Biology, Faculty of Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Slaby O; Department of Biology, Faculty of Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Mudry P; Department of Paediatric Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Cernopolni 212/9, 613 00, Brno, Czech Republic. .; International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic. .
Sterba J; Department of Paediatric Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Cernopolni 212/9, 613 00, Brno, Czech Republic.; International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Jun 28; Vol. 13 (1), pp. 10499. Date of Electronic Publication: 2023 Jun 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Phosphatidylinositol 3-Kinases*/genetics
Quality of Life*
Humans ; Prospective Studies ; Class I Phosphatidylinositol 3-Kinases/genetics ; Mutation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Endothelial hyperactivation of mutant MAP3K3 induces cerebral cavernous malformation enhanced by PIK3CA GOF mutation.
Autorzy:
Huo R; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119S Fourth Ring Rd W, Fengtai District, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Yang Y; Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China.
Sun Y; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119S Fourth Ring Rd W, Fengtai District, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Zhou Q; Division of Life Science and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China.
Zhao S; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119S Fourth Ring Rd W, Fengtai District, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Mo Z; Division of Life Science and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China.
Xu H; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119S Fourth Ring Rd W, Fengtai District, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Wang J; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119S Fourth Ring Rd W, Fengtai District, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Weng J; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119S Fourth Ring Rd W, Fengtai District, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Jiao Y; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119S Fourth Ring Rd W, Fengtai District, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Zhang J; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119S Fourth Ring Rd W, Fengtai District, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
He Q; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119S Fourth Ring Rd W, Fengtai District, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Wang S; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119S Fourth Ring Rd W, Fengtai District, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Zhao J; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119S Fourth Ring Rd W, Fengtai District, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Wang J; Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China. .; Division of Life Science and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China. .; Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong SAR, China. .
Cao Y; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119S Fourth Ring Rd W, Fengtai District, Beijing, China. .; China National Clinical Research Center for Neurological Diseases, Beijing, China. .; Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. .; Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Beijing Institute of Brain Disorders, Capital Medical University, Beijing, China. .
Pokaż więcej
Źródło:
Angiogenesis [Angiogenesis] 2023 May; Vol. 26 (2), pp. 295-312. Date of Electronic Publication: 2023 Jan 31.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hemangioma, Cavernous, Central Nervous System*/genetics
Hemangioma, Cavernous, Central Nervous System*/pathology
MAP Kinase Kinase Kinase 3*/genetics
MAP Kinase Kinase Kinase 3*/metabolism
Class I Phosphatidylinositol 3-Kinases*/genetics
Class I Phosphatidylinositol 3-Kinases*/metabolism
Animals ; Mice ; Endothelial Cells/metabolism ; Endothelium/metabolism ; Mutation/genetics ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins/genetics
Czasopismo naukowe
Szczegóły
Tytuł:
PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis.
Autorzy:
Bredin HK; Department of Clinical Science, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.; Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway.
Krakstad C; Department of Clinical Science, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.; Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway.
Hoivik EA; Department of Clinical Science, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.; Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Mar 21; Vol. 18 (3), pp. e0283203. Date of Electronic Publication: 2023 Mar 21 (Print Publication: 2023).
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Endometrial Neoplasms*/pathology
Humans ; Female ; Signal Transduction ; Mutation ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dual inhibition of phosphoinositide 3-kinases delta and gamma reduces chronic B cell activation and autoantibody production in a mouse model of lupus.
Autorzy:
Olayinka-Adefemi F; Department of Immunology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Hou S; Department of Immunology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Marshall AJ; Department of Immunology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2023 May 10; Vol. 14, pp. 1115244. Date of Electronic Publication: 2023 May 10 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Phosphatidylinositol 3-Kinases*/metabolism
Autoantibodies*/metabolism
Mice ; Animals ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Disease Models, Animal ; Phosphatidylinositols ; Immunoglobulin G
Czasopismo naukowe
Szczegóły
Tytuł:
Clinical and genetic analysis of patients with segmental overgrowth features and somatic mammalian target of rapamycin (mTOR) pathway disruption: Possible novel clinical issues.
Autorzy:
Romano F; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.
Madia F; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
De Marco P; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Ognibene M; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Guerrisi S; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Scala M; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Iacomino M; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Baldassari S; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Vercellino N; Dermatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Manunza F; Dermatology Unit, Businco Hospital, ARNAS G. Brotzu, Cagliari, Italy.
Tallone R; D.O.P.O. Ambulatory for Oncologic Follow-up, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Pavanello M; Neurosurgery Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Piatelli G; Neurosurgery Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Garaventa A; Pediatric Oncology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Zara F; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.
Capra V; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Pokaż więcej
Źródło:
Birth defects research [Birth Defects Res] 2022 Dec 01; Vol. 114 (20), pp. 1440-1448. Date of Electronic Publication: 2022 Nov 08.
Typ publikacji:
Case Reports; Research Support, Non-U.S. Gov't
MeSH Terms:
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
TOR Serine-Threonine Kinases*/genetics
TOR Serine-Threonine Kinases*/metabolism
Humans ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Genetic Testing ; Mutation ; Syndrome
Raport
Szczegóły
Tytuł:
An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer.
Autorzy:
R HC; Laboratory of Integrative Genomics, Department of Integrative Biology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Kumar S U; Laboratory of Integrative Genomics, Department of Integrative Biology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
R G; Laboratory of Integrative Genomics, Department of Integrative Biology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Naayanan PJ; Siddhalaya Clinic, Chennai, Tamil Nadu, India.
Sathiyarajeswaren P; Siddha Central Research Institute (CCRS), Chennai, Tamil Nadu, India.
Devi MSS; Siddha Central Research Institute (CCRS), Chennai, Tamil Nadu, India.
K SS; Department of Radiation Oncology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, India.
Doss C GP; Laboratory of Integrative Genomics, Department of Integrative Biology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Pokaż więcej
Źródło:
Journal of cellular biochemistry [J Cell Biochem] 2023 Feb; Vol. 124 (2), pp. 188-204. Date of Electronic Publication: 2022 Dec 23.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/genetics
Cell-Free Nucleic Acids*
Phosphatidylinositol 3-Kinases*/genetics
Tumor Suppressor Protein p53*/genetics
Female ; Humans ; Adenosine Triphosphate ; Biomarkers, Tumor/genetics ; Class I Phosphatidylinositol 3-Kinases/genetics ; Molecular Docking Simulation ; Mutation
Czasopismo naukowe
Szczegóły
Tytuł:
The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.
Autorzy:
VanLandingham NK; Department of Otolaryngology - Head and Neck Surgery, University of California San Francisco, San Francisco, CA, USA.
Nazarenko A; New York Medical College, Valhalla, NY, USA.
Grandis JR; Department of Otolaryngology - Head and Neck Surgery, University of California San Francisco, San Francisco, CA, USA.
Johnson DE; Department of Otolaryngology - Head and Neck Surgery, University of California San Francisco, San Francisco, CA, USA. Electronic address: .
Pokaż więcej
Źródło:
Advances in biological regulation [Adv Biol Regul] 2023 Jan; Vol. 87, pp. 100934. Date of Electronic Publication: 2022 Nov 15.
Typ publikacji:
Review; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Phosphatidylinositol 3-Kinases*/metabolism
Neoplasms*
Humans ; Mutation ; Signal Transduction ; Phosphoinositide-3 Kinase Inhibitors ; Class I Phosphatidylinositol 3-Kinases/genetics
Czasopismo naukowe
Szczegóły
Tytuł:
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.
Autorzy:
Hanan EJ; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Braun MG; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Heald RA; Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
MacLeod C; Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
Chan C; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Clausen S; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Edgar KA; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Eigenbrot C; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Elliott R; Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
Endres N; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Friedman LS; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Gogol E; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Gu XH; Pharmaron Beijing Co., Ltd, No. 6 Taihe Road, BDA, Beijing 100176, P. R. China.
Thibodeau RH; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Jackson PS; Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
Kiefer JR; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Knight JD; Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
Nannini M; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Narukulla R; Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
Pace A; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Pang J; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Purkey HE; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Salphati L; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Sampath D; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Schmidt S; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Sideris S; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Song K; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Sujatha-Bhaskar S; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Ultsch M; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Wallweber H; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Xin J; Pharmaron Beijing Co., Ltd, No. 6 Taihe Road, BDA, Beijing 100176, P. R. China.
Yeap S; Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
Young A; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Zhong Y; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Staben ST; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Pokaż więcej
Źródło:
Journal of medicinal chemistry [J Med Chem] 2022 Dec 22; Vol. 65 (24), pp. 16589-16621. Date of Electronic Publication: 2022 Dec 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
MeSH Terms:
Phosphatidylinositol 3-Kinases*/metabolism
Breast Neoplasms*/drug therapy
Humans ; Female ; Phosphoinositide-3 Kinase Inhibitors/pharmacology ; Phosphoinositide-3 Kinase Inhibitors/therapeutic use ; Class I Phosphatidylinositol 3-Kinases/therapeutic use ; Cell Line, Tumor ; Mutation
Czasopismo naukowe
Szczegóły
Tytuł:
Syndromic vascular malformations related to the PIK3CA and RAS pathways: A clinical and imaging review.
Autorzy:
Tsujioka Y; Department of Radiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan; Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
Nozaki T; Department of Radiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan; Department of Radiology, Keio University School of Medicine, Tokyo, Japan; Department of Radiology, St. Luke's International Hospital, Tokyo, Japan. Electronic address: .
Niimi Y; Department of Neuroendovascular Therapy, St. Luke's International Hospital, Tokyo, Japan.
Starkey J; Department of Diagnostic Radiology, Division of Neuroradiology, Oregon Health & Science University, Portland, OR, USA.
Hasegawa D; Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan.
Kondo M; Department of Radiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan; Department of Radiology, St. Luke's International Hospital, Tokyo, Japan.
Enokizono M; Department of Radiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Makidono A; Department of Radiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Kono T; Department of Radiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Jinzaki M; Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
Pokaż więcej
Źródło:
Clinical imaging [Clin Imaging] 2022 Sep; Vol. 89, pp. 162-173. Date of Electronic Publication: 2022 Jul 02.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Vascular Malformations*/diagnostic imaging
Vascular Malformations*/genetics
Class I Phosphatidylinositol 3-Kinases/genetics ; Diagnostic Imaging ; Humans ; Mutation ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins c-akt/metabolism ; Quality of Life ; Signal Transduction ; Syndrome ; ras Proteins/genetics ; ras Proteins/metabolism
Czasopismo naukowe
Szczegóły
Tytuł:
Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure.
Autorzy:
Jia W; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070, China.
Luo S; School of Stomatology, Hospital of Stomatology, Tianjin Medical University, Tianjin 300070, China.
Zhao W; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070, China.
Xu W; Tianjin Institute of Pharmaceutical Research, Tianjin 300070, China.
Zhong Y; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Kong D; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070, China.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2022 Sep 21; Vol. 27 (19). Date of Electronic Publication: 2022 Sep 21.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Phosphatidylinositol 3-Kinases*/metabolism
Adenosine Triphosphate ; Class I Phosphatidylinositol 3-Kinases ; Molecular Docking Simulation ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/pharmacology ; Receptors, Antigen, B-Cell
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
Autorzy:
Menteş M; Izmir University of Economics, Faculty of Engineering, Department of Genetics and Bioengineering, 35330 Balçova, İzmir, Turkey.
Karakuzulu BB; Izmir University of Economics, Faculty of Engineering, Department of Genetics and Bioengineering, 35330 Balçova, İzmir, Turkey.
Uçar GB; Izmir University of Economics, Faculty of Engineering, Department of Genetics and Bioengineering, 35330 Balçova, İzmir, Turkey.
Yandım C; Izmir University of Economics, Faculty of Engineering, Department of Genetics and Bioengineering, 35330 Balçova, İzmir, Turkey; Izmir Biomedicine and Genome Center (IBG), Dokuz Eylül University Health Campus, 35340 İnciraltı, İzmir, Turkey. Electronic address: .
Pokaż więcej
Źródło:
Computational biology and chemistry [Comput Biol Chem] 2022 Aug; Vol. 99, pp. 107726. Date of Electronic Publication: 2022 Jul 08.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/genetics
Phosphatidylinositol 3-Kinases*/chemistry
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Adenosine Triphosphate ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Female ; Humans ; Molecular Dynamics Simulation ; Mutation ; Protein Kinase Inhibitors
Czasopismo naukowe
Szczegóły
Tytuł:
The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.
Autorzy:
Kobialka P; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Sabata H; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Vilalta O; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Gouveia L; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
Angulo-Urarte A; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Muixí L; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Zanoncello J; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Muñoz-Aznar O; Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Olaciregui NG; Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Fanlo L; 3D Chromatin Organization, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Esteve-Codina A; CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
Lavarino C; Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Javierre BM; 3D Chromatin Organization, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Celis V; Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.
Rovira C; Department of Pathology, Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.
López-Fernández S; Department of Plastic Surgery, Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain.
Baselga E; Department of Dermatology, Hospital Sant Joan de Déu, Barcelona, Spain.
Mora J; Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.; Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.
Castillo SD; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Graupera M; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
Pokaż więcej
Źródło:
EMBO molecular medicine [EMBO Mol Med] 2022 Jul 07; Vol. 14 (7), pp. e15619. Date of Electronic Publication: 2022 Jun 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Vascular Malformations*/genetics
Vascular Malformations*/metabolism
Vascular Malformations*/pathology
Aminopyridines ; Animals ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Endothelial Cells/metabolism ; Imidazoles ; Mice ; Mutation ; Protein Kinase Inhibitors/metabolism ; Proto-Oncogene Proteins c-akt/metabolism
Czasopismo naukowe
Szczegóły
Tytuł:
Mutation patterns and prognostic analysis of BRAF/KRAS/PIK3CA in colorectal cancer.
Autorzy:
Wang C; Department of Gastrointestinal Surgery, Affiliated people's Hospital (Fujian Provincial People's Hospital), Fujian University of Traditional Chinese Medicine, Fujian, China.
Pan D; Department of Pathology, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fujian, China.
Pokaż więcej
Źródło:
Journal of clinical laboratory analysis [J Clin Lab Anal] 2022 Jun; Vol. 36 (6), pp. e24444. Date of Electronic Publication: 2022 Apr 18.
Typ publikacji:
Journal Article
MeSH Terms:
Class I Phosphatidylinositol 3-Kinases*/genetics
Class I Phosphatidylinositol 3-Kinases*/metabolism
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/pathology
Proto-Oncogene Proteins B-raf*/genetics
Proto-Oncogene Proteins B-raf*/metabolism
Proto-Oncogene Proteins p21(ras)*/genetics
Proto-Oncogene Proteins p21(ras)*/metabolism
Humans ; Mutation/genetics ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Prognosis
Czasopismo naukowe
Szczegóły
Tytuł:
Inhibition of lipid kinase PIKfyve reveals a role for phosphatase Inpp4b in the regulation of PI(3)P-mediated lysosome dynamics through VPS34 activity.
Autorzy:
Saffi GT; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
Wang CA; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
Mangialardi EM; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
Vacher J; Institut de Recherches Cliniques de Montréal (IRCM), Département de Médecine, Université de Montréal, Montréal, Québec, Canada.
Botelho RJ; Department of Chemistry and Biology, Ryerson University, Toronto, Ontario, Canada.
Salmena L; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Electronic address: .
Pokaż więcej
Źródło:
The Journal of biological chemistry [J Biol Chem] 2022 Aug; Vol. 298 (8), pp. 102187. Date of Electronic Publication: 2022 Jun 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Fibroblasts*/metabolism
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Phosphoric Monoester Hydrolases/*metabolism
Animals ; Class III Phosphatidylinositol 3-Kinases/metabolism ; Lysosomes/metabolism ; Mice ; Phosphatidylinositol Phosphates/metabolism ; Phosphatidylinositols/metabolism ; Phosphoric Monoester Hydrolases/genetics
Czasopismo naukowe
Szczegóły
Tytuł:
Cellular Mechanisms Underlying B Cell Abnormalities in Patients With Gain-of-Function Mutations in the PIK3CD Gene.
Autorzy:
Wang W; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Min Q; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Lai N; Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer, Shanghai Municipal Health Commission (SMHC), Minhang Hospital, Fudan University, Shanghai, China.
Csomos K; Division of Pediatric Allergy/Immunology and Jeffrey Modell Diagnostic and Research Center, University of South Florida and Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States.
Wang Y; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Liu L; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Meng X; Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Sun J; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Hou J; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Ying W; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Zhou Q; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Sun B; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Hui X; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Ujhazi B; Division of Pediatric Allergy/Immunology and Jeffrey Modell Diagnostic and Research Center, University of South Florida and Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States.
Gordon S; Division of Pediatric Allergy/Immunology and Jeffrey Modell Diagnostic and Research Center, University of South Florida and Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States.
Buchbinder D; Division of Hematology, Children's Hospital of Orange Country (CHOC), Irvine, CA, United States.
Schuetz C; Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Butte M; Division of Immunology, Allergy, and Rheumatology, Department of Pediatrics and Jeffrey Modell Diagnostic and Research Center, University of California, Los Angeles, Los Angeles, CA, United States.
Walter JE; Division of Pediatric Allergy/Immunology and Jeffrey Modell Diagnostic and Research Center, University of South Florida and Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States.; Massachusetts General Hospital, Boston, MA, United States.
Wang X; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.; Shanghai Institute of Infectious Disease and Biosecurity, Shanghai, China.
Wang JY; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.; Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.; Department of Microbiology and Immunology, College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; Division of Biochemistry, Faculty of Pharmacy and Graduate School of Pharmaceutical Science, Keio University, Tokyo, Japan.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2022 Jun 21; Vol. 13, pp. 890073. Date of Electronic Publication: 2022 Jun 21 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gain of Function Mutation*
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Class I Phosphatidylinositol 3-Kinases/metabolism ; Immunoglobulin M/genetics ; Mutation
Czasopismo naukowe
Szczegóły
Tytuł:
Reciprocal regulation of Daxx and PIK3CA promotes colorectal cancer cell growth.
Autorzy:
Huang YS; Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan. .; The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan. .
Wu CC; Department of Surgery, Tri-Service General Hospital Keelung Branch, National Defense Medical Center, Keelung, 20244, Taiwan.
Chang CC; The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan.; International Ph.D. Program for Translational Science, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan.; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan.; Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei, 11031, Taiwan.
Huang SF; Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Miaoli County, 35053, Taiwan.
Kuo HY; Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Miaoli County, 35053, Taiwan.
Shih HM; Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan. .; The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan. .; Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Miaoli County, 35053, Taiwan. .
Pokaż więcej
Źródło:
Cellular and molecular life sciences : CMLS [Cell Mol Life Sci] 2022 Jun 19; Vol. 79 (7), pp. 367. Date of Electronic Publication: 2022 Jun 19.
Typ publikacji:
Journal Article
MeSH Terms:
Colorectal Neoplasms*/metabolism
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Cell Line, Tumor ; Cell Proliferation/genetics ; Class I Phosphatidylinositol 3-Kinases/genetics ; Co-Repressor Proteins/genetics ; Co-Repressor Proteins/metabolism ; Gene Expression Regulation, Neoplastic ; Humans ; Molecular Chaperones/genetics ; Molecular Chaperones/metabolism
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 31610

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies